Acid phosphatase: Defining a role in androgen-independent prostate cancer

Urology

Volumn 47, Issue 5, 1996, Pages 719-726

  Steineck, Gunner ^b   Kelly, William Kevin ^b   Mazumdar, Madhu ^b   Vlamis, Vaia ^b   Schwartz, Morton ^b   Scher, Howard I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALKALINE PHOSPHATASE; ANDROGEN; ESTRAMUSTINE; ETIDRONIC ACID RE 186; GEMCITABINE; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; SURAMIN; TRIMETREXATE; TUMOR MARKER; VINBLASTINE;

ACID PHOSPHATASE BLOOD LEVEL; ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REPRODUCIBILITY; SURVIVAL;

EID: 0030000896     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00017-9     Document Type: Article

References (36)

1. Gutman EB, Sproul EE, and Gutman AB: Significance of increased phosphatase activity of bone at the the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 28: 485, 1936.
2. Huggins C, and Hodges CV: Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297, 1941.
3. Whitesel JA, Donohue RE, Mani JH, Mohr S, Scanavino DJ, Augspurger RR, Biber RJ, Fauver HE, Wettlaufer JN, and Pfister RR: Acid phosphatase: its influence on the management of carcinoma of the prostate. J Urol 131: 70-72, 1984.
4. Burnett AL, Chan DW, Brendler CB, and Walsh PC: The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J Urol 148: 1832-1834, 1992.
5. Mannini D, Maver P, Aiello E, Corrado G, Vecchi F, Bellanova B, and Marengo M: Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer. Urol Res 16: 9-12, 1988.
6. Nissenkorn I, Mickey DD, Miller DB, and Soloway MS: Circadian and day-to-day variation of prostatic acid phosphatase. J Urol 127: 1122-1124, 1982.
7. Benson MC, McMahon DJ, Cooner WH, and Olsson CA: An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World J Urol 11: 206-213, 1993.
8. Scher HI, and Yagoda A: Clinical trials in prostatic cancer: methodology and controversies, in Bruce AW, and Trachtenberg J (Eds): Adenocarcinoma of the Prostate. New York, Springer-Verlag, 1987, pp 197-220.
9. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
10. Kelly WK, Scher HI, Mazumdar M, Vlarnis V, Schwartz M, and Fossa SD: Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostatic cancer. J Clin Oncol 11: 607-615, 1993.
11. Miller JI, Ahmann FR, Drach GW, Emerson SS, and Bottaccini MR: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147: 956-961, 1992.
12. Stein BS, Vangore S, and Petersen RO: Immunoperoxidase localization of prostatic antigens: comparison of primary and metastatic sites. Urology 24: 146-152, 1984.
13. de Winter JA, Trapman J, Brinkmann AO, Boersma WJ, Mulder E, Schroeder FH, Claassen E, and van der Kwast TH: Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 160: 329-332, 1990.
14. La Rocca RV, Danesi R, Cooper MR, Jamis-Dow CA, Ewing MW, Linehan WM, and Myers CE: Effect of suramin on human prostate cancer cells in vitro. J Urol 145: 393-398, 1991.
15. Roy AV, Brower ME, and Hayden JE: Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem 17: 1093-1102, 1971.
16. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, and Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988.
17. Kaplan EL, and Meier P. Non parametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481, 1958.
18. Peto R, Pike MC, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39, 1977.
19. Scher HI, Curley T, Geller N, Engstrom C, Dershaw DD, Lin SY, Fitzpatrick K, Nisselbaum J, Schwartz M, Bezirdjian L, et al. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8: 1830-1838, 1990.
20. Ghossein R, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, and Rosai J: Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 13: 1195-1200, 1995.
21. Takashi D, Tatsuo D, Hideo E, Shin-ichi I, Yoshito T, Yoshinori N, Shigero F, Takeshi K, Hisao K, Masanori H, et al: Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 53: 5350-5354, 1993.
22. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W, et al: Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 12: 2634-2639, 1994.
23. Ruckle HC, Klee GG, and Oesterling JE: Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin Proc 69: 69-79, 1994.
24. Murtha P, Tindall DJ, and Young CY: Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry 32: 6459-6464, 1993.
25. Carter HB, Partin AW, Epstein JI, Chan DW, and Walsh PC: The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. J Urol 144: 1167-1171, 1990.
26. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, and Walsh PC: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1990.
27. Johansson JE, Andersson SO, and Holmberg L: High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. Br J Urol 68: 67-73, 1991.
28. Brenckman WD Jr, Lastinger LB, and Sedor F: Unpredictable fluctuations in serum acid phosphatase activity in prostatic cancer. JAMA 245: 2501-2504, 1981.
29. Bruce AW, Mahan DE, Morales A, Clark AF, and Belville WE: An objective look at acid phosphatase determinations: a comparsion of biochemical and immunological methods. Br J Urol 51: 213-217, 1979.
30. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43: 649-659, 1994.
31. Bilhartz DL, Tindall DJ, and Oesterling JE; Prostatespecific antigen and prostatic acid phosphatase: biomolecular and physiologic characteristics. Urology 38: 95-102, 1991.
32. Anderson JR, Cain KC, and Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1: 710-719, 1983.
33. Wood DPJr, Banks ER, Humphreys S, and Rangnekar VM: Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J Histochem Cytochem 42: 505-511, 1994.
34. Cipolla B, Guille F, Moulinoux JP, Bansard JY, Roth S, Staerman F, Corbel L, Quemener V, and Lobel B: Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients. J Urol 151: 629-633, 1994.
35. Bosl GJ, Geller NL, Cirrincione C, Vogelzang NJ, Kennedy BJ, Whitmore WFJr, Vugrin D, Scher H, Nisselbaum J, and Golbey RB: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3403-3407, 1983.
36. Bosl GJ, Geller NL, Cirrincione C, Nisselbaum J, Vugrin D, Whitmore WFJr, and Golbey RB: Serum tumor markers in patients with metastatic germ cell tumors of the testes. A 10-year experience. Am J Med 75: 29-35, 1983.